Revance and Mylan to Advance Development Program for Biosimilar to BOTOX®

First neurotoxin formulation to be developed as a potential biosimilar product to BOTOX®, potentially giving Mylan access to 14 indications upon approval – – $30 million milestone payable to Revance …
( read original story …)


Advertisement